Advanced solid tumor
Conditions
Interventions
multi-modal +PD1:Treatment with anti-PD-L1 monoclonal antibody system was initiated on day 7 after ablation
multi-modal +SGN1:Ablation d1, d8 and d15 were administered intratumoral with SGN1
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Age 18-75 years old, gender is not limited; ? Advanced solid tumors with definite pathological or clinical diagnosis, primary tumors and metastases that cannot be resected or cannot tolerate or refuse to be resected; (3) If the primary lesion can not be resected or recurred, there are no serious complications such as bleeding and obstruction; ? First-line treatment failed; For those who have previously received chemotherapy, radiotherapy or local liver treatment, the interval between the last systemic treatment or local liver treatment is at least 1 month; ?Child-Pugh A or B; Bilirubin =3.0 mg/dL, creatinine =2.5 mg/dL, white blood cell count = 2.0 ×10^9/L, platelet = 100×10^9/L; ?ECOG PS =2.
Exclusion criteria
Exclusion criteria: ?Liver function Child-Pugh grade C; ? Expected survival < 3 months; ? Insufficiency or failure of important organs; ? There is active infection; (5) Uncorrectable coagulation abnormalities; ? Refractory ascites, pleural fluid or bad fluid; ? can not cooperate with the treatment; (8)The researchers determined that there were any other factors that were not suitable for inclusion or affected participants' participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 months mPFSR; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;PFS;CBR;DOR; | — |
Countries
China
Contacts
Public ContactHaiyan Hu
Shanghai Sixth People's Hospital
Outcome results
None listed